Clinicians face challenges in deciding on the use of neoadjuvant chemotherapy(NACT) for patients with estrogen receptor(ER)-positive breast cancer due to the potential for low efficacy. Progesterone receptor(PR) is a biomarker routinely evaluated in breast cancer patients prior to NACT, but there is a lack of sufficient clinical data and guideline recommendations regarding its role in treatment decision-making. This study aimed to evaluate the impact of PR status on pathological complete response in ER-positive breast cancer patients receiving NACT. Our study examined 52 ER-positive patients who received NACT. Participants were grouped into three cohorts based on PR levels: less than 1%, 1-9%, and 10% and above. The pathological complete response rate, an important indicator of overall survival, was compared across these three groups. The results of our study showed a statistically significant higher pathological complete response rate in patients with PR levels below 1%. These findings suggest that NACT may be more effective in this patient subgroup. The study findings indicate that PR status may play a role in the decision-making process for NACT in ER-positive breast cancer patients.
Ersoy et al. (Fri,) studied this question.